Search results
Results From The WOW.Com Content Network
The first successful combination chemotherapy was MOPP, introduced in 1963 for lymphomas. The term " induction regimen " refers to a chemotherapy regimen used for the initial treatment of a disease. A " maintenance regimen " refers to the ongoing use of chemotherapy to reduce the chances of a cancer recurring or to prevent an existing cancer ...
Gemcitabine, sold under the brand name Gemzar, among others, [1] is a chemotherapy medication used to treat cancers. [3] It is used to treat testicular cancer , [ 4 ] breast cancer , ovarian cancer , non-small cell lung cancer , pancreatic cancer , and bladder cancer .
Of the platinum compounds, research has shown cisplatin to be the most frequently involved in peripheral neuropathy. [3] 2) Taxanes, including paclitaxel (and protein-bound pactiltaxel e.g. abraxane), docetaxel, and cabazitaxel, are used to treat ovarian, breast, non-small cell lung, and prostate cancers. [3]
Cisplatin was the first to be developed. [9] Cisplatin is particularly effective against testicular cancer ; the cure rate was improved from 10% to 85%. [ 10 ] Similarly, the addition of cisplatin to adjuvant chemotherapy led to a marked increase in disease-free survival rates for patients with medulloblastoma - again, up to around 85%.
Cisplatin is a chemical compound with formula cis-[Pt(NH 3) 2 Cl 2]. It is a coordination complex of platinum that is used as a chemotherapy medication used to treat a number of cancers . [ 3 ] These include testicular cancer , ovarian cancer , cervical cancer , bladder cancer , head and neck cancer , esophageal cancer , lung cancer ...
In the same study, investigators compared the incidence of common 5-FU-associated grade 3/4 toxicities between the dose-adjusted people and people dosed per BSA. [23] The incidence of debilitating grades of diarrhea was reduced from 18% in the BSA-dosed group to 4% in the dose-adjusted group and serious hematologic side effects were eliminated ...
"7+3" in the context of chemotherapy is an acronym for a chemotherapy regimen that is most often used today (as of 2014) as first-line induction therapy (to induce remission) in acute myelogenous leukemia, [1] [2] excluding the acute promyelocytic leukemia form, which is better treated with ATRA and/or arsenic trioxide and requires less chemotherapy (if requires it at all, which is not always ...
The NHS Plan 2000 originally conceived of opening eight treatment centres by 2005, but by August 2005 at least 25 had been opened, with more being planned. 46 NHS treatment centres opened between 2003 and 2009, treating approximately 300,000 patients a year with high rate of patient satisfaction (>94%).